H. Lachmann, P. Quartier, A. So, and P. Hawkins, The emerging role of interleukin-1?? in autoinflammatory diseases, Arthritis & Rheumatism, vol.67, issue.Suppl, pp.314-338, 2011.
DOI : 10.1002/art.30105

I. Touitou, C. Galeotti, L. Rossi-semerano, V. Hentgen, M. Piram et al., The expanding spectrum of rare monogenic autoinflammatory diseases, Orphanet Journal of Rare Diseases, vol.8, issue.1, p.162, 2013.
DOI : 10.1186/1750-1172-8-162
URL : https://hal.archives-ouvertes.fr/inserm-00878791

S. Federici, A. Martini, and M. Gattorno, The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases, Frontiers in Immunology, vol.4, p.351, 2013.
DOI : 10.3389/fimmu.2013.00351

C. Giampietro, M. Ridene, T. Lequerre, C. Chalumeau, N. Amoura et al., Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy, Arthritis Care & Research, vol.28, issue.Suppl, pp.822-828, 2013.
DOI : 10.1002/acr.21901

K. Laskari, A. Tzioufas, and H. Moutsopoulos, Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study, Arthritis Research & Therapy, vol.13, issue.3, p.91, 2011.
DOI : 10.1084/jem.20050473

D. Nordstrom, A. Knight, R. Luukkainen, R. Van-vollenhoven, V. Rantalaiho et al., Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study, The Journal of Rheumatology, vol.39, issue.10, pp.2008-2019, 2012.
DOI : 10.3899/jrheum.111549

P. Quartier, F. Allantaz, R. Cimaz, P. Pillet, C. Messiaen et al., A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), Annals of the Rheumatic Diseases, vol.70, issue.5, pp.747-54, 2011.
DOI : 10.1136/ard.2010.134254

N. Ruperto, H. Brunner, P. Quartier, T. Constantin, N. Wulffraat et al., Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis, New England Journal of Medicine, vol.367, issue.25, pp.2396-406, 2012.
DOI : 10.1056/NEJMoa1205099

P. Hawkins, H. Lachmann, and M. Mcdermott, Interleukin-1???Receptor Antagonist in the Muckle???Wells Syndrome, New England Journal of Medicine, vol.348, issue.25, pp.2583-2587, 2003.
DOI : 10.1056/NEJM200306193482523

R. Goldbach-mansky, N. Dailey, S. Canna, A. Gelabert, J. Jones et al., Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1?? Inhibition, New England Journal of Medicine, vol.355, issue.6, pp.581-92, 2006.
DOI : 10.1056/NEJMoa055137

H. Hoffman, M. Throne, N. Amar, M. Sebai, A. Kivitz et al., Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies, Arthritis & Rheumatism, vol.365, issue.8, pp.2443-52, 2008.
DOI : 10.1002/art.23687

H. Lachmann, I. Kone-paut, J. Kuemmerle-deschner, K. Leslie, E. Hachulla et al., Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome, New England Journal of Medicine, vol.360, issue.23, pp.2416-2441, 2009.
DOI : 10.1056/NEJMoa0810787

C. Sibley, N. Plass, J. Snow, E. Wiggs, C. Brewer et al., Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes, Arthritis & Rheumatism, vol.464, issue.Suppl III, pp.2375-86, 2012.
DOI : 10.1002/art.34409

Z. Ozçakar, S. Ozdel, S. Y?lmaz, E. Kurt-?ükür, M. Ekim et al., Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis, Clin Rheumatol, 2014.

U. Meinzer, P. Quartier, J. Alexandra, V. Hentgen, and F. Retornaz, Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature, Seminars in Arthritis and Rheumatism, vol.41, issue.2, pp.265-71, 2011.
DOI : 10.1016/j.semarthrit.2010.11.003

S. Ozen, Y. Bilginer, A. Ayaz, N. Calguneri, and M. , Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine, The Journal of Rheumatology, vol.38, issue.3, pp.516-524, 2011.
DOI : 10.3899/jrheum.100718

T. Haar, N. Lachmann, H. Ozen, S. Woo, P. Uziel et al., Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review, Annals of the Rheumatic Diseases, vol.72, issue.5, pp.678-85, 2013.
DOI : 10.1136/annrheumdis-2011-201268

C. Galeotti, U. Meinzer, P. Quartier, L. Rossi-semerano, B. Bader-meunier et al., Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency, Rheumatology, vol.51, issue.10, pp.1855-1864, 2012.
DOI : 10.1093/rheumatology/kes097

M. Gattorno, M. Pelagatti, A. Meini, L. Obici, R. Barcellona et al., Persistent efficacy of anakinra in patients with tumor necrosis factor receptor???associated periodic syndrome, Arthritis & Rheumatism, vol.201, issue.5, pp.1516-1536, 2008.
DOI : 10.1002/art.23475

E. Besada and H. Nossent, Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler???s syndrome: a case report and literature review, Clinical Rheumatology, vol.27, issue.9, pp.567-71, 2010.
DOI : 10.1007/s10067-010-1375-9

H. De-koning, E. Bodar, A. Simon, J. Van-der-hilst, M. Netea et al., Beneficial response to anakinra and thalidomide in Schnitzler's syndrome, Annals of the Rheumatic Diseases, vol.65, issue.4, pp.542-546, 2006.
DOI : 10.1136/ard.2005.045245

J. Gran, O. Midtvedt, S. Haug, and P. Aukrust, Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature, Scandinavian Journal of Rheumatology, vol.4, issue.1, pp.74-83, 2011.
DOI : 10.3109/03009742.2010.493894

P. Szturz, A. Sediva, M. Zurek, Z. Adam, J. Stork et al., Anakinra treatment in Schnitzler syndrome -results of the first retrospective multicenter study in six patients from the Czech Republic]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, pp.111-137, 2014.

M. Viguier, P. Guigue, C. Pages, A. Smahi, and H. Bachelez, Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations, Annals of Internal Medicine, vol.153, issue.1, pp.66-73, 2010.
DOI : 10.7326/0003-4819-153-1-201007060-00030

U. Huffmeier, M. Watzold, J. Mohr, M. Schon, and R. Mossner, mutations, British Journal of Dermatology, vol.286, issue.1, pp.202-206, 2014.
DOI : 10.1111/bjd.12548

L. Rossi-semerano, M. Piram, C. Chiaverini, D. Ricaud, D. Smahi et al., First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra, PEDIATRICS, vol.132, issue.4, pp.1043-1050, 2013.
DOI : 10.1542/peds.2012-3935

F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, vol.20, issue.7081, pp.237-278, 2006.
DOI : 10.1038/nature04516

N. Schlesinger, R. Alten, T. Bardin, H. Schumacher, M. Bloch et al., Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions, Annals of the Rheumatic Diseases, vol.71, issue.11, pp.1839-1887, 2012.
DOI : 10.1136/annrheumdis-2011-200908

S. Ottaviani, A. Molto, H. Ea, S. Neveu, G. Gill et al., Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases, Arthritis Research & Therapy, vol.15, issue.5, p.123, 2013.
DOI : 10.1016/j.jbspin.2012.07.018

P. Ghosh, M. Cho, G. Rawat, P. Simkin, and G. Gardner, Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra, Arthritis Care & Research, vol.64, issue.Suppl, pp.1381-1385, 2013.
DOI : 10.1002/acr.21989

T. Lequerre, P. Quartier, D. Rosellini, F. Alaoui, D. Bandt et al., Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France, Annals of the Rheumatic Diseases, vol.67, issue.3, pp.302-310, 2008.
DOI : 10.1136/ard.2007.076034

L. Lepore, G. Paloni, R. Caorsi, M. Alessio, D. Rigante et al., Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra, The Journal of Pediatrics, vol.157, issue.2, pp.310-325, 2010.
DOI : 10.1016/j.jpeds.2010.02.040

A. Fleischmann, R. Tesser, J. Schiff, M. Schechtman, J. Burmester et al., Safety of extended treatment with anakinra in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.8, pp.1006-1018, 2006.
DOI : 10.1136/ard.2005.048371

E. Behrens, T. Beukelman, M. Paessler, and R. Cron, Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis, J Rheumatol, vol.34, pp.1133-1141, 2007.

J. Bleesing, A. Prada, D. Siegel, J. Villanueva, J. Olson et al., The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor ??-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis, Arthritis & Rheumatism, vol.146, issue.3, pp.965-71, 2007.
DOI : 10.1002/art.22416

P. Miettunen, A. Narendran, A. Jayanthan, E. Behrens, and R. Cron, Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients, Rheumatology, vol.50, issue.2, pp.417-426, 2011.
DOI : 10.1093/rheumatology/keq218

B. Neven, I. Marvillet, C. Terrada, A. Ferster, N. Boddaert et al., Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome, Arthritis & Rheumatism, vol.58, issue.1, pp.258-67, 2010.
DOI : 10.1002/art.25057

J. Kuemmerle-deschner, P. Tyrrell, I. Koetter, H. Wittkowski, A. Bialkowski et al., Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome, Arthritis & Rheumatism, vol.3, issue.3, pp.840-849, 2011.
DOI : 10.1002/art.30149

I. Kone-paut, K. Retornaz, J. Garnier, and B. Bader-meunier, Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra), Clin Exp Rheumatol, vol.25, p.119, 2007.